{
  "generated": "2025-11-06T07:17:05.233292+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/physiological/omega-3-musc-msk16/musculoskeletal/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "MUSC-MSK16_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "musculoskeletal_journal",
      "outcome": "strength",
      "population": "Adults with strength concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/omega-3-musc-msk16-01",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-01",
      "citation": "MUSC-MSK16_01 (2016); Journal: musculoskeletal_journal; Design: randomized controlled trial; Population: Adults with strength concerns; Outcome: strength; DOI: 10.1234/omega-3-musc-msk16-01; Adverse Events: None reported."
    },
    {
      "study_id": "MUSC-MSK16_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "musculoskeletal_journal",
      "outcome": "strength",
      "population": "Adults with strength concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/omega-3-musc-msk16-02",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-02",
      "citation": "MUSC-MSK16_02 (2017); Journal: musculoskeletal_journal; Design: randomized controlled trial; Population: Adults with strength concerns; Outcome: strength; DOI: 10.1234/omega-3-musc-msk16-02; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "MUSC-MSK16_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "musculoskeletal_journal",
      "outcome": "strength",
      "population": "Adults with strength concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/omega-3-musc-msk16-03",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-03",
      "citation": "MUSC-MSK16_03 (2018); Journal: musculoskeletal_journal; Design: randomized controlled trial; Population: Adults with strength concerns; Outcome: strength; DOI: 10.1234/omega-3-musc-msk16-03; Adverse Events: Mild GI discomfort."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/omega-3-musc-msk16-01",
      "study_ids": [
        "MUSC-MSK16_01"
      ],
      "primary_study_id": "MUSC-MSK16_01",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/omega-3-musc-msk16-02",
      "study_ids": [
        "MUSC-MSK16_02"
      ],
      "primary_study_id": "MUSC-MSK16_02",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/omega-3-musc-msk16-03",
      "study_ids": [
        "MUSC-MSK16_03"
      ],
      "primary_study_id": "MUSC-MSK16_03",
      "url": "https://doi.org/10.1234/omega-3-musc-msk16-03"
    }
  ],
  "manifest_hash": "sha256:9e65a4bf5278fad9a9b2f5c300fc1d15094a1b05eaa96e73602dc6c2c26146c2"
}
